Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Andreeff M, et al. Among authors: middleton s. Clin Cancer Res. 2016 Feb 15;22(4):868-76. doi: 10.1158/1078-0432.CCR-15-0481. Epub 2015 Oct 12. Clin Cancer Res. 2016. PMID: 26459177 Free PMC article. Clinical Trial.
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J. Patnaik A, et al. Among authors: middleton s. Cancer Chemother Pharmacol. 2015 Sep;76(3):587-95. doi: 10.1007/s00280-015-2830-8. Epub 2015 Jul 26. Cancer Chemother Pharmacol. 2015. PMID: 26210682 Clinical Trial.
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN. Ray-Coquard I, et al. Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6. Epub 2012 Oct 17. Lancet Oncol. 2012. PMID: 23084521
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Zhong H, Chen G, Jukofsky L, Geho D, Han SW, Birzele F, Bader S, Himmelein L, Cai J, Albertyn Z, Rothe M, Essioux L, Burtscher H, Middleton SA, Rueger R, Chen LC, Dangl M, Nichols G, Pierceall WE. Zhong H, et al. Among authors: middleton sa. Br J Haematol. 2015 Nov;171(3):432-5. doi: 10.1111/bjh.13411. Epub 2015 Apr 8. Br J Haematol. 2015. PMID: 25855517 Free PMC article. Clinical Trial. No abstract available.
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE. Reis B, et al. Among authors: middleton sa. Haematologica. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717. Epub 2016 Feb 11. Haematologica. 2016. PMID: 26869629 Free PMC article. Clinical Trial. No abstract available.
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Tolcher AW, et al. Among authors: middleton sa. J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529266 Free PMC article. Clinical Trial.
712 results